154 related articles for article (PubMed ID: 30147955)
1. The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes.
van Strijp D; de Witz C; Vos PC; den Biezen-Timmermans E; van Brussel A; Wrobel J; Baillie GS; Tennstedt P; Schlomm T; Heitkötter B; Huss S; Bögemann M; Houslay MD; Bangma C; Semjonow A; Hoffmann R
Prostate Cancer; 2018; 2018():5821616. PubMed ID: 30147955
[No Abstract] [Full Text] [Related]
2. The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour's TMPRSS2-ERG Fusion Status.
van Strijp D; de Witz C; Heitkötter B; Huss S; Bögemann M; Baillie GS; Houslay MD; Bangma C; Semjonow A; Hoffmann R
Prostate Cancer; 2019; 2019():8107807. PubMed ID: 31275657
[TBL] [Abstract][Full Text] [Related]
3. Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes.
Alves de Inda M; van Strijp D; den Biezen-Timmermans E; van Brussel A; Wrobel J; van Zon H; Vos P; Baillie GS; Tennstedt P; Schlomm T; Houslay MD; Bangma C; Hoffmann R
Eur Urol Focus; 2018 Apr; 4(3):376-384. PubMed ID: 28753810
[TBL] [Abstract][Full Text] [Related]
4. The CAPRA&PDE4D5/7/9 Prognostic Model Is Significantly Associated with Adverse Post-Surgical Pathology Outcomes.
Gulliver C; Huss S; Semjonow A; Baillie GS; Hoffmann R
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612262
[TBL] [Abstract][Full Text] [Related]
5. Creating a potential diagnostic for prostate cancer risk stratification (InformMDx™) by translating novel scientific discoveries concerning cAMP degrading phosphodiesterase-4D7 (PDE4D7).
Henderson DJP; Houslay MD; Bangma CH; Hoffmann R
Clin Sci (Lond); 2019 Jan; 133(2):269-286. PubMed ID: 30683712
[TBL] [Abstract][Full Text] [Related]
6. PSA density does not improve predictive accuracy of the UCSF-CAPRA score.
Parker R; Bell A; Chang K; Greenberg S; Washington SL; Cowan JE; Carroll PR; Cooperberg MR
Prostate; 2023 Jul; 83(10):922-928. PubMed ID: 37078628
[TBL] [Abstract][Full Text] [Related]
7. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
[TBL] [Abstract][Full Text] [Related]
8. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
[TBL] [Abstract][Full Text] [Related]
9. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen.
Freedland SJ; Terris MK; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Aronson WJ;
J Urol; 2004 Jun; 171(6 Pt 1):2215-20. PubMed ID: 15126788
[TBL] [Abstract][Full Text] [Related]
10. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
11. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Oncological Outcomes After Radical Prostatectomy According to Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores: Results from a Large, Two-center Experience.
Leyh-Bannurah SR; Dell'Oglio P; Zaffuto E; Briganti A; Schiffmann J; Pompe RS; Tilki D; Heinzer H; Graefen M; Karakiewicz PI; Budäus L
Eur Urol Focus; 2019 Jul; 5(4):568-576. PubMed ID: 29129756
[TBL] [Abstract][Full Text] [Related]
13. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
14. Comparison of MRI-Based Staging and Pathologic Staging for Predicting Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy.
Merriman KM; Harmon SA; Belue MJ; Yilmaz EC; Blake Z; Lay NS; Phelps TE; Merino MJ; Parnes HL; Law YM; Gurram S; Wood BJ; Choyke PL; Pinto PA; Turkbey B
AJR Am J Roentgenol; 2023 Dec; 221(6):773-787. PubMed ID: 37404084
[No Abstract] [Full Text] [Related]
15. Clinical utility of percent prostate needle biopsy tissue with cancer cutpoints to risk stratify patients before radical prostatectomy.
Freedland SJ; Csathy GS; Dorey F; Aronson WJ
Urology; 2002 Jul; 60(1):84-8. PubMed ID: 12100929
[TBL] [Abstract][Full Text] [Related]
16. Reduced PDE4D7 in prostate cancer correlates with genomic downregulation within the upstream PDE4D coding region.
Gulliver C; Baillie GS; Hoffmann R
Future Sci OA; 2023 Oct; 9(9):FSO888. PubMed ID: 37752916
[TBL] [Abstract][Full Text] [Related]
17. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
[TBL] [Abstract][Full Text] [Related]
18. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.
Cooperberg MR; Pasta DJ; Elkin EP; Litwin MS; Latini DM; Du Chane J; Carroll PR
J Urol; 2005 Jun; 173(6):1938-42. PubMed ID: 15879786
[TBL] [Abstract][Full Text] [Related]
19. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
